3-OST-1 Regulation of Antithrombin Isoform Partitioning
3-OST-1 抗凝血酶异构体分配的调节
基本信息
- 批准号:7094648
- 负责人:
- 金额:$ 40.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-06-12 至 2010-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Dysregulation of endothelial cell mediated anti-inflammatory pathways can lead to cardiovascular disease, the leading killer in the western world, and severe sepsis, which accounts for 220,000 deaths/year in the United States. Our long term goal is to elucidate novel anti-inflammatory processes of endothelial cells, which may lead to new approaches to combat severe sepsis, heart attack and stroke. Antithrombin (AT) is a blood protein that, in part, prevents inflammation through the existence of multiple isoforms (beta-AT, alpha-AT, L- AT); however, the anti-inflammatory mechanisms are poorly understood. beta-AT preferentially partitions to the blood vessel wall and is considered to exhibit high anti-inflammatory activity. Thus, partitioning of specific AT forms may convey a strong anti-inflammatory tone to the blood vessel wall. Partitioning may also serve to enhance the stability of anti-inflammatory AT isoforms, for AT forms that lack partitioning are extremely short-lived. AT biology is thought to be regulated by an endothelial cells component called HSAT+. However, it is unclear whether HSAT+ is involved in AT partitioning and anti-inflammatory activity. We have determined that HSAT+ is required for endothelial cell internalization of AT and seek to evaluate the involvement of HSAT+ and AT endocytosis in AT partitioning and AT anti-inflammatory activity. We propose to: (1) Evaluate the role of HSAT+ in the anti-inflammatory activity of AT. This will be accomplished by studying the efficacy of AT therapy in treating septic shock induced in HSAT+ deficient or wild-type mice. (2) Elucidate molecular mechanisms by which HSAT+ mediates AT internalization. Cell biologic experiments will be conducted to determine if AT anti-inflammatory signaling is associated with a unique pathway of AT internalization. (3) Establish the role of HSAT+ in regulating the partitioning of distinct AT isoforms. To examine if HSAT+ preferentially influences the vascular partitioning and longevity of AT forms with high anti-inflammatory activity, we shall use novel molecular imaging techniques to follow the partitioning and fate of AT isoforms injected into HSAT+ deficient or wild-type mice. Together, these Aims will demonstrate novel roles for HSAT+ and provide foundations for elucidating the involvement of HSAT+ mediated AT partitioning in protecting against inflammatory processes of the cardiovascular system. Lay description: Vascular inflammation is a common denominator of numerous major diseases, such as heart attack and stroke, which are the leading killers in the western world. The body normally inhibits vascular inflammation and we wish to discover molecules involved in this processes. Such a discovery could lead to the development of novel therapeutics to combat the devastating consequences of vascular inflammation.
描述(由申请人提供):内皮细胞介导的抗炎途径失调可导致心血管疾病,这是西方世界的主要杀手,以及严重的败血症,在美国每年造成22万人死亡。我们的长期目标是阐明内皮细胞的新型抗炎过程,这可能会导致对抗严重败血症,心脏病发作和中风的新方法。抗凝血酶(AT)是一种血液蛋白,部分通过多种亚型(β -AT, α -AT, L- AT)的存在来预防炎症;然而,人们对其抗炎机制知之甚少。β - at优先进入血管壁,被认为具有高抗炎活性。因此,特定AT形式的分配可能向血管壁传递强烈的抗炎基调。分配也可能有助于增强抗炎AT异构体的稳定性,因为缺乏分配的AT异构体寿命极短。AT生物学被认为是由内皮细胞成分HSAT+调节的。然而,HSAT+是否参与AT分配和抗炎活性尚不清楚。我们已经确定HSAT+是AT内皮细胞内化所必需的,并试图评估HSAT+和AT内吞作用在AT分配和AT抗炎活性中的作用。我们建议:(1)评估HSAT+在AT抗炎活性中的作用。这将通过研究AT治疗HSAT+缺陷或野生型小鼠感染性休克的疗效来实现。(2)阐明HSAT+介导AT内化的分子机制。将进行细胞生物学实验以确定AT抗炎信号是否与AT内化的独特途径有关。(3)确立HSAT+在调节不同AT亚型分配中的作用。为了研究HSAT+是否优先影响具有高抗炎活性的AT形式的血管分配和寿命,我们将使用新的分子成像技术来跟踪注射到HSAT+缺陷或野生型小鼠的AT异构体的分配和命运。总之,这些目标将证明HSAT+的新作用,并为阐明HSAT+介导的AT分配在心血管系统炎症过程中的保护作用提供基础。概要描述:血管炎症是许多主要疾病的共同特征,如心脏病发作和中风,这是西方世界的主要杀手。身体通常会抑制血管炎症,我们希望发现参与这一过程的分子。这一发现可能会导致新的治疗方法的发展,以对抗血管炎症的破坏性后果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NICHOLAS W SHWORAK其他文献
NICHOLAS W SHWORAK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NICHOLAS W SHWORAK', 18)}}的其他基金
3-OST-1 Regulation of Antithrombin Isoform Partitioning
3-OST-1 抗凝血酶异构体分配的调节
- 批准号:
7428808 - 财政年份:2006
- 资助金额:
$ 40.76万 - 项目类别:
3-OST-1 Regulation of Antithrombin Isoform Partitioning
3-OST-1 抗凝血酶异构体分配的调节
- 批准号:
7245886 - 财政年份:2006
- 资助金额:
$ 40.76万 - 项目类别:
3-OST-1 Regulation of Antithrombin Isoform Partitioning
3-OST-1 抗凝血酶异构体分配的调节
- 批准号:
7626790 - 财政年份:2006
- 资助金额:
$ 40.76万 - 项目类别:
相似海外基金
Novel mechanisms linking blood coagulation to liver fibrosis
将凝血与肝纤维化联系起来的新机制
- 批准号:
10722686 - 财政年份:2023
- 资助金额:
$ 40.76万 - 项目类别:
Lipid peroxidation- and pyroptosis-induced tissue factor activation in pathogen-induced blood coagulation
病原体诱导的血液凝固中脂质过氧化和焦亡诱导的组织因子激活
- 批准号:
10571353 - 财政年份:2023
- 资助金额:
$ 40.76万 - 项目类别:
Elucidation of changes in electrical properties during the blood coagulation process and its use for measurement of blood coagulation status during extracorporeal circulation
阐明血液凝固过程中电特性的变化及其在体外循环期间血液凝固状态测量中的应用
- 批准号:
23K08266 - 财政年份:2023
- 资助金额:
$ 40.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
SBIR Phase II: Innovative Platform for Low Volume Blood Coagulation Analysis
SBIR II 期:低容量凝血分析的创新平台
- 批准号:
2134020 - 财政年份:2022
- 资助金额:
$ 40.76万 - 项目类别:
Cooperative Agreement
Construction of a multilayered network to represent blood coagulation process
构建代表血液凝固过程的多层网络
- 批准号:
22K12252 - 财政年份:2022
- 资助金额:
$ 40.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Protein S Regulates Blood Coagulation by Inhibiting Factor IXa
Protein S 通过抑制 IXa 因子调节凝血
- 批准号:
10616732 - 财政年份:2022
- 资助金额:
$ 40.76万 - 项目类别:
Development of thrombus prevention technology for ECMO devices based on the blood coagulation mechanism caused by viral infections
基于病毒感染凝血机制的ECMO装置血栓预防技术开发
- 批准号:
21K08817 - 财政年份:2021
- 资助金额:
$ 40.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Novel mechanisms linking blood coagulation to liver fibrosis
将凝血与肝纤维化联系起来的新机制
- 批准号:
10452687 - 财政年份:2021
- 资助金额:
$ 40.76万 - 项目类别:
SBIR Phase II: CoagCare-A POC Blood Coagulation Diagnostic Platform That Utilizes A Hand-held Meter and Mechanically Sensitive Test Strips for Broad Spectrum Hemostasis Monitoring
SBIR II 期:CoagCare - POC 凝血诊断平台,利用手持式仪表和机械敏感试纸条进行广谱止血监测
- 批准号:
2050272 - 财政年份:2021
- 资助金额:
$ 40.76万 - 项目类别:
Cooperative Agreement
Novel mechanisms linking blood coagulation to liver fibrosis
将凝血与肝纤维化联系起来的新机制
- 批准号:
10283268 - 财政年份:2021
- 资助金额:
$ 40.76万 - 项目类别:














{{item.name}}会员




